List of Excipients in Branded Drug CORDRAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Almirall LLC	CORDRAN	flurandrenolide	16110-035	CETYL ALCOHOL
Almirall LLC	CORDRAN	flurandrenolide	16110-035	CITRIC ACID MONOHYDRATE
Almirall LLC	CORDRAN	flurandrenolide	16110-035	MINERAL OIL
Almirall LLC	CORDRAN	flurandrenolide	16110-035	POLYOXYL 40 STEARATE
Almirall LLC	CORDRAN	flurandrenolide	16110-035	PROPYLENE GLYCOL
Almirall LLC	CORDRAN	flurandrenolide	16110-035	SODIUM CITRATE
Almirall LLC	CORDRAN	flurandrenolide	16110-035	STEARIC ACID

CORDRAN Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

CORDRAN is a legacy topical flurandrenolide product line with commercial value concentrated in formulation differentiation rather than molecule-level exclusivity. The strongest opportunity is a portfolio of dermatologic formulations that preserve corticosteroid performance while improving spreadability, tolerability, adhesion, storage stability, and manufacturing economics. CORDRAN Tape is the most defensible dosage form because its adhesive delivery system creates greater technical barriers than conventional creams, ointments, and lotions.

What is CORDRAN and which formulations are commercially relevant?

CORDRAN contains flurandrenolide, a fluorinated topical corticosteroid used for inflammatory and pruritic corticosteroid-responsive dermatoses. The product line has included cream, ointment, lotion, and medicated tape presentations. The tape delivers flurandrenolide from an adhesive matrix and is used for localized lesions requiring occlusion or sustained contact.[1]

Product presentation	Active ingredient	Primary formulation function	Commercial position
Cream	Flurandrenolide 0.05%	Balanced spreadability and washability	Broadest generic opportunity
Ointment	Flurandrenolide 0.05%	Occlusion and emolliency	Useful for dry, thickened lesions
Lotion	Flurandrenolide 0.05%	Lower-viscosity application to larger or hair-bearing areas	Differentiated sensory profile
Tape	Flurandrenolide 4 mcg/cm²	Adhesive occlusion and prolonged contact	Highest formulation and manufacturing barrier

Flurandrenolide is an established active ingredient. The commercial question is therefore less about discovering a new molecule and more about controlling delivery, product usability, manufacturing yield, and regulatory comparability.

What excipients are used in CORDRAN formulations?

The excipients vary by dosage form because each vehicle performs a different delivery function. Public labeling identifies conventional dermatologic excipient systems, including petrolatum or mineral-oil components in semisolid products and alcohol, humectant, cellulose, or water-based systems in lotion products.[1,2]

CORDRAN cream excipient strategy

A cream vehicle generally uses an oil phase, an aqueous phase, emulsifiers, fatty alcohols, humectants, and preservatives where required. The primary objectives are:

• Maintain flurandrenolide uniformity throughout the emulsion.
• Provide adequate skin deposition without excessive greasiness.
• Support acceptable rub-in and wash-off characteristics.
• Prevent phase separation over the labeled shelf life.
• Control microbial growth in the aqueous phase.

Typical excipient classes include cetostearyl or related fatty alcohols, glycols, nonionic emulsifiers, hydrocarbons, purified water, and preservatives. A generic developer should not treat these materials as interchangeable. Changes in emulsifier ratio, internal phase volume, particle size, or preservative system can alter drug release and skin permeation.

The strongest commercial formulation target is a low-grease cream with rapid rub-in and low residue. Patients often select topical corticosteroids based on vehicle acceptability, particularly for visible or frequently treated areas. A formulation with equivalent corticosteroid strength but better cosmetic performance can support pharmacy substitution resistance, prescriber preference, and private-label positioning.

CORDRAN ointment excipient strategy

Ointments rely on a hydrophobic base, typically involving petrolatum and mineral-oil components. The formulation provides:

• High occlusion.
• Reduced transepidermal water loss.
• Strong performance on dry, lichenified, or fissured lesions.
• Lower dependence on aqueous-phase preservative systems.

The principal disadvantages are greasiness, transfer to clothing, and lower patient acceptance in warm climates. Commercial improvement should focus on reducing tack while maintaining occlusion. Options include controlled incorporation of light mineral oils, hydrogenated hydrocarbons, silicone-compatible emollients, or alternative semi-solid structuring systems.

Any change must preserve drug solubilization or dispersion, spreadability, drug release, and physical stability. A less occlusive ointment may improve consumer acceptance but could lose the clinical and performance attributes associated with the reference product.

CORDRAN lotion excipient strategy

A lotion is designed for easier application over larger areas, hairy skin, or areas where an ointment is impractical. The vehicle may include volatile alcohols, glycerin or another humectant, water, and a viscosity modifier such as a cellulose derivative.[1]

The key excipient risks are:

• Stinging from alcohol or low-pH systems.
• Drying caused by volatile solvents.
• Flocculation or sedimentation.
• Viscosity drift during storage.
• Dose variability from inadequate suspension uniformity.

A high-value reformulation would improve moisturization and reduce sting without making the lotion sticky. A sprayable or foam-like presentation could expand use on larger areas, but it would likely require a new dosage-form development program rather than a straightforward generic approach.

CORDRAN Tape excipient and adhesive strategy

CORDRAN Tape is the most technically differentiated presentation. Its performance depends on more than the active ingredient. Critical materials include:

• Pressure-sensitive adhesive.
• Backing layer.
• Release liner.
• Drug-loading system.
• Permeation and occlusion characteristics.
• Adhesive coat weight.
• Cutability and edge integrity.

The tape must adhere to skin for the intended wear period without excessive irritation or residue. It must also release the correct quantity of flurandrenolide during use. Small changes in adhesive chemistry, drug solubility, crystallization, coat weight, backing permeability, or liner release force can change product performance.

Tape development has a higher barrier to entry than cream or ointment development because the applicant must control adhesive manufacturing, content uniformity across the web, roll-to-roll processing, packaging, and human-use performance. These barriers create commercial opportunity for contract manufacturers with transdermal and topical adhesive capabilities.

Which excipient attributes create the greatest commercial advantage?

The most valuable attributes are patient acceptability, reproducible drug release, manufacturing robustness, and packaging compatibility.

Attribute	Commercial benefit	Main technical risk
Low greasiness	Better adherence and repeat use	Reduced occlusion or drug retention
Fast rub-in	Improved patient preference	Faster evaporation and crystallization
Low sting	Better use on sensitive skin	Preservative or solvent instability
Strong adhesion	Longer contact time for tape	Irritation and residue
Controlled occlusion	Improved lesion hydration	Maceration or excess absorption
Preservative reduction	Differentiation for sensitive-skin users	Microbial-control failure
Stable viscosity	Consistent dosing and appearance	Temperature-dependent flow
Low-cost raw materials	Improved gross margin	Greater batch variability

Formulation teams should prioritize performance attributes that can be demonstrated in comparative studies. Cosmetic claims alone are commercially weak unless supported by measurable spreadability, residue, adhesion, irritation, or use-time data.

What regulatory pathway applies to CORDRAN generics?

Conventional CORDRAN cream, ointment, and lotion products are generally candidates for abbreviated new drug application development if an approved reference product and applicable FDA product-specific guidance support the pathway. The applicant must establish pharmaceutical equivalence and demonstrate bioequivalence under the applicable FDA framework.[3]

For topical dermatologic products, sameness of active ingredient and strength is not sufficient. The formulation may require close control of:

• Qualitative and quantitative composition.
• Particle size or drug-state characteristics.
• pH.
• Globule or droplet size.
• Viscosity and rheology.
• In vitro release.
• Microstructure.
• Packaging and container-closure interaction.

FDA’s topical dermatologic guidance recognizes that formulation attributes can influence local availability even when systemic exposure is limited.[3]

Cream, ointment, and lotion regulatory risk

The regulatory risk is lowest for a compositionally close cream or ointment with a well-characterized reference product. Risk increases when the applicant changes:

• Emulsifier class.
• Preservative system.
• Solvent composition.
• Drug particle size.
• Rheology modifier.
• Packaging format.
• Manufacturing process.

A reformulated product with a materially different vehicle may still be approvable, but it could require additional comparative clinical or pharmacodynamic evidence. That reduces the cost and speed advantage of an ANDA.

Tape regulatory risk

CORDRAN Tape presents a higher regulatory burden. An applicant must address adhesive performance, drug release, adhesion, irritation, sensitization, dose uniformity, and stability. A tape cannot be treated as a cream placed on a backing. The adhesive matrix is part of the drug-delivery system.

A successful tape program requires specialized analytical methods and process controls. These include drug extraction from adhesive, uniformity mapping across the coated web, in vitro release testing, adhesion testing, peel testing, and accelerated stability studies.

What patents protect CORDRAN and when does exclusivity end?

Flurandrenolide is an old corticosteroid, and molecule-level patent protection is not the principal commercial barrier for CORDRAN. The relevant protection historically has been more likely to involve dosage-form construction, adhesive systems, manufacturing processes, or specific therapeutic uses than the active ingredient itself.

The practical exclusivity assessment is:

Protection category	Relevance to CORDRAN	Commercial impact
Active-ingredient patent	Low for an old corticosteroid	Does not normally block generic flurandrenolide development
Basic cream or ointment formulation	Limited unless a later patent claims a specific composition	Usually weak barrier
Tape adhesive or delivery system	Potentially meaningful	Can delay or complicate entry
Manufacturing process	Relevant where process is difficult to reproduce	May create know-how barriers
Method-of-use patent	Potentially relevant if listed and enforceable	Depends on claim scope and indication
FDA exclusivity	Product-specific and time-limited	Must be confirmed in current FDA records

A current Orange Book review is necessary before a launch decision because listed patents, delisting events, certifications, and regulatory status can change. For an old topical product, the larger risk often lies in reference-product availability, product-specific guidance, bioequivalence expectations, and manufacturing execution rather than a blocking composition patent.

Are Paragraph IV challenges and generic launch opportunities material?

The generic opportunity is strongest for cream and ointment products because those dosage forms have established manufacturing platforms and relatively accessible excipient systems. A Paragraph IV strategy would be most relevant if a current listed patent covers a tape adhesive, a specific vehicle, or a later method of use.

Potential launch scenarios include:

1. First generic cream entry. This could capture substitution-driven volume if the reference product has meaningful pharmacy utilization.
2. Multi-source ointment entry. Competition would likely focus on price, availability, and payer preference.
3. Authorized-generic or private-label supply. A manufacturer could use a compliant formulation platform to supply distributors or dermatology-focused marketers.
4. Tape challenge or licensed entry. The value is higher per unit, but technical and regulatory execution is substantially harder.
5. 505(b)(2) reformulation. A new vehicle, spray, foam, or improved tape could support differentiated positioning but would require a stronger clinical and regulatory package than a conventional ANDA.

Paragraph IV economics depend on whether the product has active listed patents and whether the challenger can establish a non-infringement or invalidity position. The commercial value of a challenge should be discounted if the reference product has low volume or if the market has limited reimbursement.

What formulation patents and manufacturing IP could be valuable?

The most commercially useful intellectual property would protect measurable performance attributes rather than generic excipient lists. Examples include:

• A defined adhesive composition with specified flurandrenolide release.
• A tape with controlled drug loading per unit area.
• A low-irritation adhesive with defined peel and shear properties.
• A cream with a specified microstructure or droplet-size distribution.
• A preservative-reduced formulation with validated microbial protection.
• A stable suspension lotion with controlled particle-size distribution.
• A process that prevents flurandrenolide crystallization during drying or storage.
• A package that limits solvent loss or adhesive migration.

Patent claims limited to broad classes such as “a corticosteroid and a pharmaceutically acceptable carrier” are vulnerable to prior-art challenges. Stronger claims use narrow compositional ranges linked to release, stability, adhesion, or skin-deposition data.

Trade secrets may be more important than patents for tape products. Coating speed, drying conditions, adhesive mixing order, web tension, drug dispersion, and liner handling can materially affect yield and product quality.

How does CORDRAN compare with competing topical corticosteroids?

CORDRAN competes with other topical corticosteroid products across potency, vehicle, price, and availability. The market includes hydrocortisone, triamcinolone acetonide, fluocinonide, betamethasone products, and other prescription corticosteroids.

Competitive factor	CORDRAN opportunity	Competitive pressure
Active ingredient	Established clinical use	Many alternative corticosteroids
Tape delivery	Limited direct competition	Higher development complexity
Cream and ointment	Familiar dosage forms	Significant generic price pressure
Lotion	Useful for hair-bearing areas	Many established lotion products
Potency positioning	Supports prescription use	Prescribers may prefer newer or cheaper agents
Patient adherence	Vehicle can differentiate	Generic substitution reduces branding power
Payer access	Potential for low-cost generic supply	Formulary pressure favors commodity products

CORDRAN Tape has the clearest niche because the delivery format can provide localized occlusion and sustained contact. Cream and ointment opportunities are more dependent on manufacturing cost and distribution scale.

What licensing and partnership opportunities exist?

The most credible partnership targets are:

• A dermatology company with an established sales force.
• A contract development and manufacturing organization with topical semisolid capacity.
• An adhesive-product manufacturer with coated-web capabilities.
• A generic pharmaceutical company seeking a differentiated dermatology product.
• A specialty pharmacy or distributor with access to dermatology practices.

Licensing economics differ by dosage form. Cream and ointment products generally support lower development costs but face greater price erosion. Tape products can support higher gross margins, but they require greater upfront investment and may depend on specialized manufacturing assets.

A practical deal structure could separate territories, dosage forms, or channels. For example, one partner could commercialize cream and ointment products while another funds tape development. Manufacturing rights should address adhesive raw-material qualification, batch release, change control, and supply continuity.

What revenue exposure and commercial risks should investors evaluate?

Revenue potential depends on five variables:

1. Reference-product sales and prescription volume.
2. Number of approved generic competitors.
3. Reimbursement and substitution rates.
4. Product availability and manufacturing yield.
5. Mix between conventional semisolids and tape.

Cream and ointment products can reach market faster but may experience rapid price erosion after multiple entrants. Tape has a smaller addressable market but may maintain better pricing because fewer manufacturers can reproduce the product and satisfy regulatory requirements.

The principal risks are:

• Low market demand for an older corticosteroid.
• Difficulty obtaining or characterizing the reference product.
• Failure to match topical performance.
• Adhesive irritation or inadequate wear time.
• Raw-material variability.
• Preservative-related stability or microbiological failures.
• Limited payer willingness to reimburse a differentiated formulation.
• Manufacturing scale-up losses, particularly for tape coating.

Key Takeaways

• CORDRAN’s commercial value is concentrated in formulation and delivery-system execution, not active-ingredient exclusivity.
• Cream and ointment products offer the lowest-cost generic entry but face substantial price competition.
• Lotion development can differentiate through sensory performance, moisturization, and reduced sting.
• CORDRAN Tape has the strongest technical barrier because adhesive, backing, release, adhesion, and drug-release attributes must be controlled together.
• A close-composition ANDA is likely to be more efficient than a materially reformulated product.
• Formulation patents should claim defined performance-linked compositions or processes rather than broad excipient categories.
• Tape manufacturing know-how may provide stronger practical protection than a broad formulation patent.
• Current Orange Book listings, reference-product status, and any active litigation or settlement terms should be reviewed before investment or launch decisions.
• Biosimilar risk is not relevant because flurandrenolide is a small-molecule corticosteroid, not a biologic.
• The highest-value opportunity is a technically differentiated tape or patient-preferred cream supported by reliable manufacturing and dermatology-focused distribution.

FAQs

Is CORDRAN a biologic or biosimilar product?

No. CORDRAN contains flurandrenolide, a synthetic small-molecule corticosteroid. Generic development proceeds through the abbreviated new drug application framework rather than the biosimilar pathway.

Which CORDRAN dosage form has the strongest barrier to generic competition?

CORDRAN Tape has the strongest barrier because it requires adhesive-system replication, drug-loading uniformity, controlled release, skin adhesion, irritation testing, and specialized manufacturing.

Can a generic CORDRAN cream use different excipients?

Yes, subject to the applicable FDA equivalence requirements. A formulation with different excipients may face greater development and bioequivalence risk, particularly if the changes affect microstructure, drug release, viscosity, or skin permeation.

Are preservatives necessary in CORDRAN cream or lotion?

They may be necessary in aqueous formulations, but the requirement depends on the specific vehicle, packaging system, water activity, manufacturing process, and validated preservative-effectiveness results. Hydrophobic ointments generally have different microbiological-control requirements.

What is the best commercial positioning for a new CORDRAN product?

A low-grease, low-sting cream offers the broadest market opportunity. A redesigned adhesive tape offers greater differentiation and potentially stronger pricing, but it requires substantially more technical and regulatory investment.

References

1. DailyMed. (n.d.). Cordran: Flurandrenolide cream, ointment, lotion, and tape prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
3. U.S. Food and Drug Administration. (2022). Acyclovir topical cream; clobetasol propionate topical products; and other topical dermatological drug products: Product-specific guidance and topical dermatological bioequivalence principles.
4. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary, General Chapters on semisolid dosage forms, topical products, and preservative effectiveness. United States Pharmacopeial Convention.